Medical radiotheranostics, a revolutionary concept in cancer care, integrates diagnosis and therapy, enhancing the precision and efficacy of treatments. This innovative approach utilises radiolabelled compounds that can both image and treat malignancies, offering a dual benefit that has significantly advanced the field of nuclear medicine.
The term ‘radiotheranostics’ combines ‘radiotherapy’ and ‘diagnostics’, reflecting its dual functionality. It involves the use of specific molecules that bind to cancer cells and are tagged with radioactive isotopes. These isotopes are carefully chosen so that their emitted radiation can be detected by imaging techniques such as Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT), allowing for precise tumour localisation. Following imaging, the same radioactive isotopes deliver targeted radiation therapy, destroying the cancer cells while minimising damage to surrounding healthy tissue.
One of the pivotal elements of radiotheranostics is the selection of appropriate targets on cancer cells, such as receptors or antigens that are overexpressed in certain tumour types. For example, the prostate-specific membrane antigen (PSMA) is used as a target in prostate cancer. Radiolabelled molecules that bind to PSMA can be visualised to assess the extent and location of the cancer and then used to deliver lethal doses of radiation directly to the tumour cells.
This targeted approach offers several advantages over traditional methods. Firstly, it allows for the assessment of the biodistribution of the radiopharmaceutical, ensuring that it accumulates sufficiently within the tumour before commencing therapeutic radiation. This leads to a more tailored treatment plan based on the individual’s specific disease presentation, which can result in improved efficacy and reduced side effects. Additionally, radiotheranostics can provide vital information on tumour response early in the treatment course, enabling adjustments to be made if necessary.
Another significant benefit of radiotheranostics is its potential in treating metastatic diseases, which are often difficult to manage with conventional therapies. For instance, Lutetium-177 PSMA therapy has shown promising results in patients with metastatic castration-resistant prostate cancer, providing a new lifeline where previous therapies have failed.
The future of medical radiotheranostics looks promising as research continues to evolve. New targets are being explored, and advances in molecular biology and imaging technology are likely to expand the range of cancers that can be treated with this method. Moreover, developing novel radiolabelled compounds that can be used for diagnostic and therapeutic purposes is set further to enhance the effectiveness and safety of cancer treatments, heralding a new era in personalised medicine. As this field grows, it holds the potential to significantly alter the landscape of cancer treatment, offering hope to those battling this complex disease.
You are here:
home »
By
| 7 minutes of readingLearn how radiotheranostics in cancer care combines imaging and therapy for better outcomes in advanced malignancies.
Radiotheranostics: The Dual Power of Diagnosis and Therapy in Modern Medicine Read Article »
By
| 7 minutes of readingFind out how radiotheranostics medicine is transforming cancer therapy by merging diagnostics with targeted radionuclide therapy.
By
| 9 minutes of readingLearn about theranostics and why it differs from radiotheranostics. Tailor treatments with advanced diagnostics.
Theranostics vs Radiotheranostics: Understanding the Difference Read Article »
By
| 13 minutes of readingRadioactive isotopes emit targeted radiation that effectively destroys cancer cells while minimising harm to healthy tissues.
Biological Principles Underpinning Targeted Radionuclide Therapy for Cancer Read Article »
By
| 10 minutes of readingYttrium-90 Tabituximab barzuxetan is a radiolabelled drug designed for targeted synovial sarcoma treatment.
By
| 11 minutes of readingYttrium-90 OPS201, a receptor antagonist, delivers targeted beta radiation for effective neuroendocrine tumour therapy and research.
Yttrium-90 OPS201: A Potential Breakthrough in Neuroendocrine Tumour Therapy Read Article »
By
| 11 minutes of readingZevalin therapy combines monoclonal antibody targeting with Yttrium-90 radiation to treat non-Hodgkin’s lymphoma effectively.
By
| 11 minutes of readingFerritarg therapy targets acidic ferritin in cancer cells, offering precision treatment for refractory Hodgkin’s disease and other malignancies.
Ferritarg: A Multifaceted Antibody Approach for Targeted Cancer Therapy Read Article »
By
| 10 minutes of readingYttrium-90 FAPi-46 targets fibroblast activation protein, providing effective radiotherapy for tumours and fibrotic diseases.
By
| 9 minutes of readingYttrium-90 FAPi-04 is a promising radiotherapeutic targeting fibroblast activation protein in cancer-associated fibroblasts effectively.
Yttrium-90 FAPi-04: A Novel Radiotherapeutic Targeting Fibroblast Activation Protein Read Article »
By
| 10 minutes of readingYttrium-90 Epratuzumab Tetraxetan enhances Non-Hodgkin Lymphoma treatment through targeted radioimmunotherapy and durable responses.
By
| 10 minutes of readingYttrium-90 Edotreotide delivers targeted beta radiation therapy to somatostatin receptor-positive neuroendocrine tumours with precision.
By
| 11 minutes of readingYttrium-90 DOTA-FF-21101 targets P-Cadherin in solid tumours, delivering beta radiation for precise cancer treatment.
By
| 11 minutes of readingYttrium-90 Besilesomab targets CD66-expressing cells, providing precise beta radiation therapy for systemic amyloid light chain amyloidosis.
By
| 11 minutes of readingYttrium-90 Anditixafortide targets CXCR4-expressing tumours, delivering therapeutic β– radiation precisely, improving treatment outcomes significantly.
By
| 10 minutes of readingThorium-227 Anetumab Corixetan delivers targeted alpha radiation, effectively treating mesothelin-expressing tumours while sparing healthy tissues.
By
| 12 minutes of readingTerbium-161 PSMA-I&T combines precise PSMA targeting with beta and Auger emissions, revolutionising prostate cancer treatment efficacy.
Terbium-161 PSMA-I&T: A New Frontier in Targeted Radioligand Therapy Read Article »
By
| 11 minutes of readingTin-117m DTPA offers innovative treatment options for bone metastases, combining therapeutic efficacy with minimal collateral tissue damage.
The Rise, Fall, and Revival of Tin-117m DTPA Read Article »
By
| 11 minutes of readingTin-117m DOTA-Annexin V revolutionises medicine by simultaneously imaging and treating vulnerable plaques, cancers, and neuroinflammation.
By
| 13 minutes of readingSamarium-153 DOTMP, a promising radiopharmaceutical, targets bone metastases effectively while allowing precise imaging for clinical monitoring.
Samarium-153 DOTMP (CycloSAM): A Renaissance in Bone Pain Palliation Read Article »
By
| 4 minutes of readingRhenium-188 SSS/Lipiodol combines targeted delivery with beta radiation, offering hope for advanced hepatocellular carcinoma patients.
By
| 7 minutes of readingRhenium-188 Colloidal Sulfide provides targeted radiation therapy, reducing joint inflammation and pain in large rheumatoid arthritis-affected joints.
By
| 14 minutes of readingRhenium-188 HDD/Lipiodol therapy offers targeted radiopharmaceutical treatment for advanced hepatocellular carcinoma with portal vein thrombosis.
By
| 13 minutes of readingRhenium-188 P2045 is a peptide-based radiopharmaceutical targeting somatostatin receptors for treating neuroendocrine and pancreatic cancers.
By
| 11 minutes of readingRhenium-188 Etidronate effectively targets metastatic bone lesions, delivering therapeutic beta radiation while reducing associated pain.
By
| 13 minutes of readingRhenium-188 ImDendrim combines targeted nitro-imidazole ligands and dendrimers to deliver beta radiation to hypoxic tumours.
By
| 12 minutes of readingLead-203 DOTA-VMT-MCR1 binds MC1R with high specificity, facilitating targeted imaging and image-guided therapy for metastatic melanoma patients.
By
| 10 minutes of readingLead-212 VMT-α-NET offers advanced targeted therapy for neuroendocrine tumours by harnessing precise alpha-particle radiation.
By
| 13 minutes of readingLead-212 DOTAMTATE targets somatostatin receptors in neuroendocrine tumours, delivering potent alpha-emission therapy with minimal off-target toxicity.
Lead-212 DOTAMTATE: A Novel Alpha-Emitting Therapy for Neuroendocrine Tumours Read Article »
By
| 5 minutes of readingPhosphorus-32 Colloidal Chromic Phosphate delivers precise beta radiation for treating malignant effusions and cystic tumours.
By
| 5 minutes of readingLutetium-177 XT033 combines PSMA targeting and Evans blue technology to improve metabolic stability and therapeutic effectiveness.
